Sansure Biotech Inc (688289) — Cash Flow Quality Index
Sansure Biotech Inc (688289) has a Cash Flow Quality Index of 2.09x as of September 2025. Operating cash flow of CN¥59.72 Million exceeds net income of CN¥28.60 Million, indicating high earnings quality where cash backs reported profits. Explore Sansure Biotech Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sansure Biotech Inc Cash Flow Quality Index (2018–2025)
Historical Cash Flow Quality Index for Sansure Biotech Inc across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Sansure Biotech Inc cash conversion from operations.
Annual Cash Flow Quality Index for Sansure Biotech Inc (2018–2025)
Year-by-year earnings quality comparison for Sansure Biotech Inc.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.93x | CN¥183.96 Million | CN¥198.15 Million | ▼ -23.5% |
| 2024 | 1.21x | CN¥274.45 Million | CN¥226.27 Million | ▲ +274.3% |
| 2023 | 0.32x | CN¥112.82 Million | CN¥348.17 Million | ▼ -75.5% |
| 2022 | 1.32x | CN¥2.56 Billion | CN¥1.94 Billion | ▲ +57.9% |
| 2021 | 0.84x | CN¥1.88 Billion | CN¥2.24 Billion | ▼ -17.1% |
| 2020 | 1.01x | CN¥2.64 Billion | CN¥2.62 Billion | ▲ +77.9% |
| 2019 | 0.57x | CN¥22.41 Million | CN¥39.48 Million | ▼ -61.9% |
| 2018 | 1.49x | CN¥10.07 Million | CN¥6.76 Million | — |